Shilpa Medicare Limited

Equities

SHILPAMED

INE790G01031

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:47 2024-04-18 am EDT 5-day change 1st Jan Change
526 INR -2.67% Intraday chart for Shilpa Medicare Limited +2.71% +59.20%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US MT
Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit MT
Shilpa Medicare Gets Board Nod to Launch QIP MT
Shilpa Medicare's Life Science Arm Names CEO MT
Shilpa Medicare's New Unit in Hyderabad, India Gets Zero Observations from US FDA MT
Shilpa Medicare Gets Approval to Market Smoking Cessation Drug in Europe MT
Transcript : Shilpa Medicare Limited, Q3 2024 Earnings Call, Feb 12, 2024
Shilpa Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Shilpa Medicare Gets Germany's Marketing Approval for Rare Muscles Diseases Drug MT
Shilpa Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Shilpa Medicare Acquires US-Based Pilnova Pharma MT
Shilpa Medicare Limited Launches Naturally Derived Option for the Treatment of Oral Mucositis in India Under the Brand Name Oraal CI
Shilpa Medicare Unit's API Manufacturing Plant Gets Clearance from Japanese Drug Regulator's Inspection MT
Shilpa Medicare Gets UK Drug Regulator's Nod to Market Drug for Meniere's Syndrome Symptoms MT
Shilpa Medicare Limited Receives Marketing Authorization from MHRA, UK, for Betahistine Dihydrochloride Orodispersible Films, 24 mg CI
Shilpa Medicare's Manufacturing Facility in Telangana Gets Clearance from Brazilian Regulator MT
Transcript : Shilpa Medicare Limited, Q1 2024 Earnings Call, Aug 11, 2023
Shilpa Medicare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Shilpa Medicare Limited Announces Issuance of Redeemable Non-Convertible Debentures for its 2 Wholly Owned Subsidiaries CI
Shilpa Medicare Gets Regulatory Nod for Pemetrexed Injections MT
Shilpa Medicare Limited Receives Approval from CDSCO, New Delhi for Manufacturing and Sale of Lenvatinib Capsules, 12, 18 and 24 mg in India CI
Shilpa Medicare to Raise Up to INR3.25 Billion from Rights Issue MT
Shilpa Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Shilpa Medicare Limited Announces New Drug Application for Pemetrexed Injection 1000 mg/100 ml, 500 mg/50 mg/50 mg & 100 mg/10 mg/10 mgl, Ready to Use Form Form Formulation Is Approved By US FDA CI
Shilpa Medicare Limited Announces US FDA GMP Inspection Cleared with VAI Classification CI
Chart Shilpa Medicare Limited
More charts
Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in research and development, manufacturing and sale of oncology drugs and formulations. Its products consist of oncology and non-oncology active pharmaceutical ingredients (APIs), oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. It supplies oncology APIs and intermediates. Its oncology/non-oncology APIs include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib HCL, and Irinotecan HCL Trihydrate for various regulated markets, including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India. It is also engaged in manufacturing and sale of Lenvatinib Capsules under the brand name Lenshil.
More about the company

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. SHILPAMED Stock
  4. News Shilpa Medicare Limited
  5. Market Chatter: Shilpa Medicare's Drug for Psoriatic Arthritis Gets Tentative Nod by US Drug Regulator